The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice
- PMID: 23413984
- DOI: 10.1111/apt.12240
The aspirin cardiovascular/gastrointestinal risk calculator--a tool to aid clinicians in practice
Abstract
Background: Assessment of both GI and CV risks vs. the benefits of low-dose aspirin for individual patients can be difficult in clinical practice.
Aim: To develop a tool to estimate CV and GI risks to facilitate the clinical decision-making process.
Methods: We constructed risk-ratio estimations and determined the incidence of CV events and upper GI complications according to the presence of different risk factors. For upper GI complications we assumed a baseline incidence of 1 case/1000-persons-year, a twofold increased risk with low-dose aspirin, and estimated a 60% GI risk reduction with proton pump inhibitors (PPI) co-therapy and a 60% risk reduction with H. pylori eradication in patients with a history of peptic ulcer.
Results: The calculator can be found at http://www.asariskcalculator.com. In patients with low CV risk the number of GI complications induced by low-dose aspirin may be greater than the number of CV events prevented. In patients with high CV risk, low-dose aspirin is recommended, but the number of GI complications induced may still overcome the CV events saved. The use of PPI reduces the number of complication events induced by low-dose aspirin, but the number of CV events saved may still be offset by the number of GI complications induced in patients at very high GI risk.
Conclusions: There are many clinical situations where the number of potential upper GI complications induced by low-dose aspirin may exceed the number of potentially prevented CV events. A risk calculator should guide physicians in choosing appropriate therapy and maximise the aspirin benefit.
© 2013 Blackwell Publishing Ltd.
Comment in
-
Letter: the burden of co-morbidity in the population contributes more to upper gastrointestinal bleeding than aspirin.Aliment Pharmacol Ther. 2013 Jun;37(11):1115. doi: 10.1111/apt.12308. Aliment Pharmacol Ther. 2013. PMID: 23656421 No abstract available.
-
Letter: the burden of co-morbidity in the population contributes more to upper gastrointestinal bleeding than aspirin--authors' reply.Aliment Pharmacol Ther. 2013 Jun;37(11):1116. doi: 10.1111/apt.12320. Aliment Pharmacol Ther. 2013. PMID: 23656423 No abstract available.
Similar articles
-
A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005. Clin Ther. 2009. PMID: 19843493
-
Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.Aliment Pharmacol Ther. 2011 Jul;34(2):243-51. doi: 10.1111/j.1365-2036.2011.04707.x. Epub 2011 May 25. Aliment Pharmacol Ther. 2011. PMID: 21615437
-
Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.Aliment Pharmacol Ther. 2009 Mar 1;29(5):481-96. doi: 10.1111/j.1365-2036.2008.03905.x. Epub 2008 Nov 27. Aliment Pharmacol Ther. 2009. PMID: 19053986
-
Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Clin Ther. 2010. PMID: 20435236 Review.
-
Strategies to reduce the GI risks of antiplatelet therapy.Rev Cardiovasc Med. 2005;6 Suppl 4:S23-31. Rev Cardiovasc Med. 2005. PMID: 17710073 Review.
Cited by
-
Physicians' perceptions and awareness of adverse effects of proton pump inhibitors and impact on prescribing patterns.Front Pharmacol. 2024 Jun 26;15:1383698. doi: 10.3389/fphar.2024.1383698. eCollection 2024. Front Pharmacol. 2024. PMID: 38989150 Free PMC article.
-
Needs-based considerations for the role of low-dose aspirin along the CV risk continuum.Am J Prev Cardiol. 2024 Apr 15;18:100675. doi: 10.1016/j.ajpc.2024.100675. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38694728 Free PMC article.
-
Evaluating physicians' awareness and prescribing trends regarding proton pump inhibitors: a cross-sectional study.Front Pharmacol. 2023 Nov 9;14:1241766. doi: 10.3389/fphar.2023.1241766. eCollection 2023. Front Pharmacol. 2023. PMID: 38026957 Free PMC article.
-
Evidence-based Role of Aspirin in Giant Cell Arteritis: A Literature Review.J Community Hosp Intern Med Perspect. 2022 Sep 9;12(5):11-16. doi: 10.55729/2000-9666.1072. eCollection 2022. J Community Hosp Intern Med Perspect. 2022. PMID: 36262497 Free PMC article. Review.
-
Aspirin for prevention of colorectal cancer in the elderly: friend or foe?Ann Gastroenterol. 2021;34(1):1-11. doi: 10.20524/aog.2020.0556. Epub 2020 Nov 20. Ann Gastroenterol. 2021. PMID: 33414615 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
